Citigroup clarified that it is very much in the home loan business and has just sold a small portion of its loan-book (5%) so that it can lend afresh
Financial services firm Religare Enterprises today said it will acquire a part of Citigroup India's home loan portfolio for Rs500 crore, representing 5% of the latter's total mortgage book, reports PTI.
Citigroup clarified that it is very much in the home loan business and has just sold a small portion of its loan-book so that it can lend afresh. The acquisition would be done through the non-banking finance arm Religare Finvest and is expected to be completed by October.
"We have entered into an agreement to acquire part assets of Citigroup India's mortgage portfolio for Rs500 crore. The deal would be completed in the next three months," Religare Finvest chief executive Kavi Arora told PTI.
He said Religare Finvest has been in the home-loan business for the last three years and the acquisition of key assets of Citi's mortgage business would give it an edge.
The acquisition is the first by Religare Finvest since it started offering loans for SME commercial vehicles and construction equipment in the third quarter of 2008.
Citi South Asia chief financial officer Abhijit Sen said, "This sale is of a small pool of mortgages representing less than 5% of our total mortgage portfolio. Citibank routinely sells small tranches of its portfolio to optimise returns on capital and such assets sold are substituted by fresh loan."
Mortgages are a priority business for Citi and a core part of the bouquet of products and services offered to customers, Mr Arora added.
Citi's total mortgage portfolio is Rs9,000-Rs10,000 crore and its total loan-book is about Rs40,000 crore.
Religare Finvest is a wholly-owned subsidiary of Religare Enterprises and is registered with the RBI as a non-banking finance company (NBFC). It currently provides consumer finance, Initial public offer (IPO) financing and personal financial services. The NBFC is present in 23 cities and employs over 400.
The market is likely to witness a flat to small gap-down opening on mixed cues from across the globe on concerns about the pace of the economic recovery. Wall Street ended flat on Thursday after the markets recovered early losses on dismal economic data. Bourses in Asia were trading mixed on US worries. Back home, the Sensex settled at 17,909, down 28 points (0.1%) and the Nifty ended Thursday’s session at 5,378, down 7 points (0.1%). The indices traded range-bound in the morning session. The benchmarks witnessed a fall in the early afternoon session; however, the market recovered, taking cues from the European market, which staged a recovery after opening weak. Gains were pared towards the end of the session with the market ending in the red.
US markets ended flat after they recovered early losses buoyed by a recovery in Goldman Sachs and British Petroleum shares. The Philadelphia Federal Reserve Bank said factory activity in the mid-Atlantic region fell unexpectedly, while the New York Federal Reserve Bank said New York manufacturing hit the lowest since December 2009. The US Labor Department said the Producer Price Index declined for a third straight month. In June, the PPI fell 0.5%, against a marginal decline forecast by analysts.
Meanwhile, the US senate passed the Financial Regulatory Bill, which now awaits president Barack Obama's nod. The Dow ended 7.4 points lower (0.1%) at 11,741, the S&P 500 ended 1.3 points higher (0.1%) at 1,096 and the Nasdaq ended 2.8 points higher (0.5%) at 1,856.
Markets in Asia were trading on a mixed note on the last trading day of the week on global economic concerns as consumer spending in the US slowed down in the US. The development ignited worries for Asian exporters. Shanghai Composite and Nikkei 500 were trading with cuts of 0.80% to 1.60%. Hang Seng and Straits Times were up between 0.05% and 0.21%. The SGX Nifty was at 5,380 down 4.50 points, indicating a cautious opening for the Indian markets.
India’s annual food inflation was up to 12.81% for the week ended 3rd July while fuel inflation was up 14.27%. In the previous week, food inflation was at 12.63% and fuel inflation was at 18.02%, government data on Thursday indicated.
Chambal Fertiliser, Nava Bharat Ventures and Rallis India are among the companies, which are set to declare their quarterly numbers today. Chambal Fertiliser’s March quarter sales and operating profit were down 17% and 4% respectively. Nava Bharat Venture’s March quarter sales and operating profit were up 4% and 12% respectively. Rallis India’s sales and operating profit were up 13% and 119% respectively.
The government is all set to expand drug price control. But can it ensure implementation of the prescribed prices?
The Union ministry of chemicals and fertilisers is set to invoke the 'public interest' clause under the drug price control order to bring a massive 354 essential drugs and medicines under a price cap as against a mere 74 today. This move will mark a policy reversal after several years of lobbying by the drug and pharmaceutical industry, which had succeeded in whittling down the list of price-controlled drugs from 347 to 74 over the past three decades.
While this is an important move from the consumers' perspective, a lot will depend on the lobbying powers of the industry. According to industry sources, "There have been some moves from chemicals and fertilisers minister MK Alagiri, who has asked the National Pharmaceutical Pricing Authority (NPPA) to write to the law ministry to process the order."
Meanwhile, several top drug company lobbyists are understood to have rushed to New Delhi to convince the ministry against such drastic action. According to our source, the move could be "stillborn" unless the minister receives support from the prime minister and the Congress high command.
Under the proposed move, the NPPA list of 354 'price-controlled' drugs will cover a market size of Rs7,000 crore. These will be listed under the National List of Essential Medicines (NLEM).
Dr Chandra M Gulhati, editor, Monthly Index of Medical Specialities says, "The objective of the drug price regulation is that people should get quality drugs at affordable prices. Over the years, the number of drugs under price control has been steadily decreased from 347 (in 1979), to 142 (in 1987), 76 (in 1995) to just 74 currently (at least 20 molecules currently under the Drugs Price Control Order (DPCO) are hardly being used - such as captopril, chlorpromazine, phenylbutazone etc). But for a legal stay granted by the Karnataka High Court, the number would have come down to just 34 as per the Pharmaceutical Policy (2002). This corresponds to less than 5% of all major molecules in India. Therefore, there is an urgent need to enlarge the scope of the DPCO."
The Supreme Court had in a directive set aside the national pharmaceutical policy in 2003 and asked the government to formulate appropriate criteria to bring all essential and life-saving medicines under price control. Under pressure from the pharmaceutical industry, the government has been dragging its feet on this issue for several years.
S Srinivasan, managing trustee, LOCOST, Baroda, told Moneylife, "I hope it is true - we have had several false alarms in the past - and one hopes the move does not stumble at the legal level or breaks down because of some anti-price regulation voices in the Cabinet. Any such move also needs to be accompanied by clearer powers to the NPPA. NPPA must itself modify its price ceiling methodology to something simple and transparent; and most importantly as recommended by the Pronab Sen Committee, any irrational fixed dose combination of these single ingredient drugs should have the same ceiling price." LOCOST (Low Cost Standard Therapeutics) is a non-profit organisation that makes essential medicines and sells them at affordable prices.
NPPA is an autonomous body attached to the ministry of chemicals and fertilisers, but needs to refer nearly all cases to the ministry before issuing orders. Critics say that if a medicine comes under price control, the company adds another ingredient and takes licensing approval to market it as a new product.
RP Yajurvedi (Rao), president, Society for Awareness of Civil Rights (an NGO based in Mumbai) said, "This is a welcome step from the ministry and has been long overdue. It should be proactive to implement the proposal. This breaking news will obviously have drug companies lobbying to scuttle the proposal."
Dr Gulhati said, "This is very vague news. Such a move has been on and off for many years. It is not so simple a matter. Moreover, the ministry of chemicals is not the sole entity to decide. What about the ministry of health? What about the Group of Ministers under Sharad Pawar? What about the pending case in the Supreme Court? Currently, the post-manufacturing mark-up is 100% under DPCO. Will the same yardstick be applied to all new entrants into the DPCO regime? If so, the domestic industry will close down. The mark-up will need to be hiked to at least 300%."
Clearly it is a long battle and a lot will depend on the lobbying power and clout of the pharmaceutical industry, which is bound to pull out every stop to prevent an expansion of the price-control list